Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma
<i>Background</i>: Prostaglandin E2 (PGE2) is metabolized to prostaglandin E-major urinary metabolite (PGE-MUM). Enhanced cyclooxygenase-2 (COX-2) expression demonstrated in lung adenocarcinoma indicates increased PGE-MUM levels in patients with lung adenocarcinoma. <i>Objectives&l...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/11/6/768 |
| _version_ | 1797766636604751872 |
|---|---|
| author | Hironori Kawamoto Hiromichi Hara Jun Araya Akihiro Ichikawa Yu Fujita Hirofumi Utsumi Mitsuo Hashimoto Hiroshi Wakui Shunsuke Minagawa Takanori Numata Seiji Arihiro Tomokazu Matsuura Mutsunori Fujiwara Satoru Ito Kazuyoshi Kuwano |
| author_facet | Hironori Kawamoto Hiromichi Hara Jun Araya Akihiro Ichikawa Yu Fujita Hirofumi Utsumi Mitsuo Hashimoto Hiroshi Wakui Shunsuke Minagawa Takanori Numata Seiji Arihiro Tomokazu Matsuura Mutsunori Fujiwara Satoru Ito Kazuyoshi Kuwano |
| author_sort | Hironori Kawamoto |
| collection | DOAJ |
| description | <i>Background</i>: Prostaglandin E2 (PGE2) is metabolized to prostaglandin E-major urinary metabolite (PGE-MUM). Enhanced cyclooxygenase-2 (COX-2) expression demonstrated in lung adenocarcinoma indicates increased PGE-MUM levels in patients with lung adenocarcinoma. <i>Objectives</i>: We aimed to elucidate the clinical usefulness of measuring PGE-MUM as an indicator of tumor burden in patients with lung adenocarcinoma. <i>Methods:</i> PGE-MUM was measured by a radioimmunoassay in control healthy volunteers (<i>n</i> = 124) and patients with lung adenocarcinoma (<i>n</i> = 54). Associations between PGE-MUM levels and clinical characteristics of the patients (including lung cancer stage and TNM factors (T: Tumor, N: Node, M: Metastasis) were examined. <i>Results:</i> PGE-MUM levels were significantly elevated in patients with lung adenocarcinoma. A PGE-MUM level of 14.9 μg/g∙Cr showed 70.4% sensitivity and 67.7% specificity for the diagnosis of lung adenocarcinoma. PGE-MUM levels tended to be positively correlated with cancer progression as determined by the TNM staging system. Advanced stage (stage III, stage IV, and recurrence) was significantly associated with high PGE-MUM levels by logistic regression analysis. No apparent correlation was demonstrated between PGE-MUM and carcinoma embryonic antigen (CEA) levels. <i>Conclusions</i>: PGE-MUM can be a promising biomarker reflecting the systemic tumor burden of lung adenocarcinoma. |
| first_indexed | 2024-03-12T20:28:02Z |
| format | Article |
| id | doaj.art-1bb10b4ab2ae4b28b2e892b1f7b73a45 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T20:28:02Z |
| publishDate | 2019-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-1bb10b4ab2ae4b28b2e892b1f7b73a452023-08-02T00:18:44ZengMDPI AGCancers2072-66942019-06-0111676810.3390/cancers11060768cancers11060768Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung AdenocarcinomaHironori Kawamoto0Hiromichi Hara1Jun Araya2Akihiro Ichikawa3Yu Fujita4Hirofumi Utsumi5Mitsuo Hashimoto6Hiroshi Wakui7Shunsuke Minagawa8Takanori Numata9Seiji Arihiro10Tomokazu Matsuura11Mutsunori Fujiwara12Satoru Ito13Kazuyoshi Kuwano14Division of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, JapanDivision of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, JapanDivision of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, JapanDivision of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, JapanDivision of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, JapanDivision of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, JapanDivision of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, JapanDivision of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, JapanDivision of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, JapanDivision of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, JapanDivision of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, JapanDepartment of Laboratory Medicine, School of Medicine, Jikei University, Tokyo 105-8471, JapanDepartment of Clinical Pathology, Japanese Red Cross Medical Center, Tokyo 150-8935, JapanIDAC Theranostics, Inc.; Tokyo 113-0033, JapanDivision of Respiratory diseases, Department of Internal Medicine, School of Medicine, Jikei University, Tokyo 105-8471, Japan<i>Background</i>: Prostaglandin E2 (PGE2) is metabolized to prostaglandin E-major urinary metabolite (PGE-MUM). Enhanced cyclooxygenase-2 (COX-2) expression demonstrated in lung adenocarcinoma indicates increased PGE-MUM levels in patients with lung adenocarcinoma. <i>Objectives</i>: We aimed to elucidate the clinical usefulness of measuring PGE-MUM as an indicator of tumor burden in patients with lung adenocarcinoma. <i>Methods:</i> PGE-MUM was measured by a radioimmunoassay in control healthy volunteers (<i>n</i> = 124) and patients with lung adenocarcinoma (<i>n</i> = 54). Associations between PGE-MUM levels and clinical characteristics of the patients (including lung cancer stage and TNM factors (T: Tumor, N: Node, M: Metastasis) were examined. <i>Results:</i> PGE-MUM levels were significantly elevated in patients with lung adenocarcinoma. A PGE-MUM level of 14.9 μg/g∙Cr showed 70.4% sensitivity and 67.7% specificity for the diagnosis of lung adenocarcinoma. PGE-MUM levels tended to be positively correlated with cancer progression as determined by the TNM staging system. Advanced stage (stage III, stage IV, and recurrence) was significantly associated with high PGE-MUM levels by logistic regression analysis. No apparent correlation was demonstrated between PGE-MUM and carcinoma embryonic antigen (CEA) levels. <i>Conclusions</i>: PGE-MUM can be a promising biomarker reflecting the systemic tumor burden of lung adenocarcinoma.https://www.mdpi.com/2072-6694/11/6/768PGE-MUMlung adenocarcinomabiomarker |
| spellingShingle | Hironori Kawamoto Hiromichi Hara Jun Araya Akihiro Ichikawa Yu Fujita Hirofumi Utsumi Mitsuo Hashimoto Hiroshi Wakui Shunsuke Minagawa Takanori Numata Seiji Arihiro Tomokazu Matsuura Mutsunori Fujiwara Satoru Ito Kazuyoshi Kuwano Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma Cancers PGE-MUM lung adenocarcinoma biomarker |
| title | Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma |
| title_full | Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma |
| title_fullStr | Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma |
| title_full_unstemmed | Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma |
| title_short | Prostaglandin E-Major Urinary Metabolite (PGE-MUM) as a Tumor Marker for Lung Adenocarcinoma |
| title_sort | prostaglandin e major urinary metabolite pge mum as a tumor marker for lung adenocarcinoma |
| topic | PGE-MUM lung adenocarcinoma biomarker |
| url | https://www.mdpi.com/2072-6694/11/6/768 |
| work_keys_str_mv | AT hironorikawamoto prostaglandinemajorurinarymetabolitepgemumasatumormarkerforlungadenocarcinoma AT hiromichihara prostaglandinemajorurinarymetabolitepgemumasatumormarkerforlungadenocarcinoma AT junaraya prostaglandinemajorurinarymetabolitepgemumasatumormarkerforlungadenocarcinoma AT akihiroichikawa prostaglandinemajorurinarymetabolitepgemumasatumormarkerforlungadenocarcinoma AT yufujita prostaglandinemajorurinarymetabolitepgemumasatumormarkerforlungadenocarcinoma AT hirofumiutsumi prostaglandinemajorurinarymetabolitepgemumasatumormarkerforlungadenocarcinoma AT mitsuohashimoto prostaglandinemajorurinarymetabolitepgemumasatumormarkerforlungadenocarcinoma AT hiroshiwakui prostaglandinemajorurinarymetabolitepgemumasatumormarkerforlungadenocarcinoma AT shunsukeminagawa prostaglandinemajorurinarymetabolitepgemumasatumormarkerforlungadenocarcinoma AT takanorinumata prostaglandinemajorurinarymetabolitepgemumasatumormarkerforlungadenocarcinoma AT seijiarihiro prostaglandinemajorurinarymetabolitepgemumasatumormarkerforlungadenocarcinoma AT tomokazumatsuura prostaglandinemajorurinarymetabolitepgemumasatumormarkerforlungadenocarcinoma AT mutsunorifujiwara prostaglandinemajorurinarymetabolitepgemumasatumormarkerforlungadenocarcinoma AT satoruito prostaglandinemajorurinarymetabolitepgemumasatumormarkerforlungadenocarcinoma AT kazuyoshikuwano prostaglandinemajorurinarymetabolitepgemumasatumormarkerforlungadenocarcinoma |